BioLargo, Inc. (BLGO) Stock Price & Analysis
BioLargo, Inc. (BLGO) — price $0.0749 (+10.38%), as of the Nov 19, 2026 trading session; market cap $25.1M.
Educational signal · not a buy or sell recommendation · How to read this
BioLargo, Inc. · BLGO
BioLargo, Inc. is an environmental engineering company focused on developing and commercializing platform technologies to address critical environmental challenges, including PFAS contamination, water purification, and industrial odor control. The company leverages numerous issued patents to offer innovative solutions and comprehensive environmental engineering services.
Price as of Nov 19, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.0749 | |
| Change on the day | +10.38% | |
| 52-week range | $0.06 – $0.20 | |
| Market capitalisation | $25.1M | — |
| Shares traded on the day | 201.9K |
Price & events
Other perspectives
Council score for BioLargo (BLGO): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is BioLargo (BLGO), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. BioLargo, Inc. (BLGO) is the company analyzed here. It employs 45 people and is led by Dennis Calvert. In Q2 FY2026 it reported revenue of $1M and net income of -$3M. The market values it at $25.1M.
What do the latest results show for BioLargo (BLGO)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $1M. Against analyst estimates the company has EPS beat 1 of the last 5 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $1M | -$3M | -$0.01 (diluted) |
| Q1 FY2026 | $1M | -$2M | -$0.01 (diluted) |
| Q4 FY2025 | $616,000 | -$3M | -$0.01 (diluted) |
| Q3 FY2025 | $1M | -$6M | -$0.02 (diluted) |
What are the financial strengths and risks for BioLargo (BLGO)?
Short answer · as of
The distress and quality screens read Altman Z -42.00 · Piotroski F 2. Trailing ratios: current ratio 0.73 · earnings yield -63.6% · free-cash-flow yield -43.6%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -42.00 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 1 of the last 5 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
The records behind this page
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 30, 2026
- Transactions
- 18
- Identified insiders
- 6
- Purchases
- 0
- Sales
- 0
- Other transactions
- 18
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held BLGO in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported BLGO in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about BioLargo (BLGO)?
- BioLargo Targets Growing Industrial PFAS Market with MasterClass at International Water Conference
- BioLargo's BEST Expands Industrial PFAS Treatment Activities Amid Major PFAS Settlements
- BioLargo Announces Launch of barebird.com
- BioLargo's Clyra Medical Gains Commercial Traction as Clinician Enthusiasm Drives Health System Adoption
Common Questions About BLGO
These answers are editorial: 1 of these 8 answers is drawn from the BLGO research dossier (written Jun 13, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is BLGO a good stock to buy?
Stock Expert AI does not rate BLGO buy, sell or hold. BioLargo, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the BLGO stock price today?
The last price recorded for BioLargo, Inc. (BLGO), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What does BioLargo, Inc. do?
BioLargo, Inc. is an environmental engineering company that invents, develops, and commercializes advanced platform technologies to solve critical environmental problems.
What are the key factors to evaluate for BLGO?
Evaluate BLGO on fundamentals, analyst consensus, and risk factors. Analysts target $0.30 (+301%). PFAS Remediation Market Expansion: The global market for PFAS remediation is experiencing rapid growth due to increasing regulatory pressures and public awareness regarding 'forever chemicals.' Not financial advice.
How frequently does BLGO data refresh on this page?
BLGO's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven BLGO's recent stock price performance?
BioLargo, Inc. (BLGO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Extensive portfolio of issued patents protecting proprietary platform technologies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BLGO overvalued or undervalued right now?
BioLargo, Inc. (BLGO) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research BLGO before investing?
Before investing in BioLargo, Inc. (BLGO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 13, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 15 figures on this page — 8 from Financial Modeling Prep (FMP) and 7 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com